With Hyderabad-based Bharat Biotech receiving an approval to conduct Phase-III trials for Covaxin, India inches closer to having its own vaccine to fight the coronavirus pandemic. This is crucial as the government plans to start vaccinating the healthcare and essential workers starting January.
The Subject Expert Committee (SEC) at Central Drugs Standard Control Organisation (CDSCO) which is reviewing proposals related to Covid-19 drugs and vaccines has granted permission to the vaccine maker to start Phase-III trials after it assessed data from the Phase-I and II trials along with the animal challenge study.
"In continuation of the SEC meeting dated 05.10.2020, the firm presented their data from Phase-I and II along with animal challenge data in two species including NHP on the Inactivated Coronavirus Vaccine (BBV152) along with the proposal to conduct event-driven Phase-III clinical trial to assess the efficacy of the vaccine," the expert panel said.
The SEC, however, has also noted that this approval is conditional, subject to the primary efficacy endpoint for symptomatic cases being amended. It has recommended that once a suspect case was confirmed, it would be evaluated to be classified as a symptomatic case. Either an RT-PCR test confirmation or, if the subject shows symptoms like shortness of breath or difficulty in breathing, it should be present to classify a case as confirmed symptomatic.
According to sources, around 28,500 people are expected to enroll for the Phase-III trials who will be given two doses of the investigational vaccine. The preliminary results of Covaxin trials have shown promising results (including immunogenicity) and not many side effects.
The SEC had asked for the safety and immunogenicity data from the ongoing Phase-II trials.
Bharat Biotech had halved the size of the Phase-II clinical trial of Covaxin to only 380 volunteers after it got good immunogenicity data from the Phase-I. Volunteers did not complain of any major side effects apart from fever and body aches.
The trial size for Phase-I and II trials was set at 1,125 candidates. Of this, 375 volunteers were vaccinated in Phase-I. So, 750 were to be a part of the Phase-II studies. For Phase-II studies, Bharat Biotech tested the vaccine on children above 12 years of age.
The firm had got the nod from the Drug Controller General of India to conduct Phase-I and II trials in July.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU